Pfizer’s ecnoglutide and Innovent Biologics’ mazdutide have passed a preliminary review to be potentially included in China’s basic medical insurance drug catalogue, a list published by the National Healthcare Security Administration showed on Monday.
The two drugs, which belong to the class of GLP-1 receptor agonist drugs, are both approved in China as treatments for weight management and type II diabetes.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
Close to home. Always in the loop.
Your trusted hub for local news, community stories, and the voices shaping your neighborhood.
A low-commitment monthly bundle that keeps your business in front of local audiences across HyperLocal Loop and the OBBM Network.
Every Patriot Package is priced at over 40% off standard AdRevv list rates — and the discount deepens as you scale, up to 60% off at the Enterprise tier.
Need a custom configuration? Build your own package →
Add the app to your home screen for a faster, full-screen experience.
